Answers are grounded in this paper and cite their sources.
Clinical observation shows decreased fibrinogen in patients treated with eravacycline, suggesting need for monitoring.
A majority of eravacycline-treated patients experienced at least a 25% decrease in fibrinogen levels. Although the decreased fibrinogen levels did not result in major clinically significant bleeding, fibrinogen levels should be monitored at baseline and at least weekly. Patients should also be monitored for any signs and symptoms of bleeding.
No takes yet. Share an insight, caveat, or question.
Stevenson et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: